Study of the Week: Researchers Identify Racial and Socioeconomic Disparities in Pediatric Bone Cancer Outcomes
source: pixabay.com

Study of the Week: Researchers Identify Racial and Socioeconomic Disparities in Pediatric Bone Cancer Outcomes

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Researchers Identify Racial and Socioeconomic Disparities in Pediatric Bone Cancer Outcomes
Racial, Ethnic, and Socioeconomic Health Inequities Lead Some Children to Have Worse Osteosarcoma Care, Outcomes
source: pixabay.com

Racial, Ethnic, and Socioeconomic Health Inequities Lead Some Children to Have Worse Osteosarcoma Care, Outcomes

The first thing that you should know: osteosarcoma (a type of bone cancer) is treatable. In fact, when you treat osteosarcoma early enough, it is curable; children can live long,…

Continue Reading Racial, Ethnic, and Socioeconomic Health Inequities Lead Some Children to Have Worse Osteosarcoma Care, Outcomes

Hockey Community Fundraises After Multiple Families Touched by Sarcoma

The Rogers, Minnesota hockey community is strong and unified; if something happens to someone in their ranks, they step up to assist. But nothing could have prepared them for the…

Continue Reading Hockey Community Fundraises After Multiple Families Touched by Sarcoma

Editor’s Choice: A Treatment for Mitochondrial Disease, Rare Pediatric Disease Designation in Osteosarcoma, and a “Chaotic” Birth

Happy Monday! This week, we have stories on a potential treatment approach for an aggressive form of mitochondrial disease, an experimental treatment for osteosarcoma earning Rare Pediatric Disease designation, and…

Continue Reading Editor’s Choice: A Treatment for Mitochondrial Disease, Rare Pediatric Disease Designation in Osteosarcoma, and a “Chaotic” Birth

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time